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Abstract
Purpose—More than 50,000 Americans were diagnosed with kidney and renal pelvis cancer in 
2010. The National Program of Cancer Registries and SEER (Surveillance, Epidemiology and End 
Results) combined data include cancer incidences from the entire United States. Our study 
presents updated incidence data, evaluates trends and adds geographic distribution to the literature.
Materials and Methods—We examined invasive, microscopically confirmed kidney and renal 
pelvis cancers diagnosed from 2001 to 2010 that met United States Cancer Statistics reporting 
criteria for each year, excluding cases diagnosed by autopsy or death certificate. Histology codes 
classified cases as renal cell carcinoma. Rates and trends were estimated using SEER*Stat.
Results—A total of 342,501 renal cell carcinoma cases were diagnosed. The renal cell carcinoma 
incidence rate increased from 10.6/100,000 individuals in 2001 to 12.4/100,000 in 2010 and 
increased with age until ages 70 to 74 years. The incidence rate in men was almost double that in 
women. The annual percent change was higher in women than in men, in those 20 to 24 years old 
and in grade III tumors.
Conclusions—The annual percent change incidence increased from 2001 to 2010. Asian/Pacific 
Islanders and 20 to 24-year-old individuals had the highest annual percent change. While some 
increase resulted from localized disease, the highest annual percent change was in grade III 
tumors, indicating more aggressive disease. Continued monitoring of trends and epidemiological 
study are warranted to determine risk factors.
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More than 50,000 individuals in the U.S. were diagnosed with cancer of the kidney and 
renal pelvis in 2010.1 RCC, an adenocarcinoma of the renal parenchyma, accounts for more 
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than 80% of kidney cancer in adults.2 Associated risk factors for RCC are cigarette 
smoking,3 obesity4 and hypertension.5 RPC arises from transitional cells of the urinary 
collecting system and accounts for less than 20% of cases.6 The primary risk factors for 
RPC include cigarette smoking7 and the use of phenacetin, an analgesic that was taken off 
the market in the early 1980s due to this association.8 Previous studies showed that the RCC 
incidence has been increasing steadily in the last 2 decades2,9 but the RPC incidence appears 
to be decreasing.9
Cancer incidence data combined from NPCR and SEER cover the entire U.S. population.10 
This expanded coverage captures more kidney cancer cases than SEER alone, allowing for 
more detailed examination of cancer rates and trends by age group, race, ethnicity and 
geographic region than previous studies.2,9 We present updated incidence data on RCC and 
characterize trends in RCC incidence by key demographic and clinical factors. We were 
particularly interested in determining whether the previous increase in the RCC incidence 
continued and if so whether the increase in the incidence differed by demographic and 
clinical factors, and geographic location.
METHODS
We used USCS data from population based registries participating in the CDC (Centers for 
Disease Control and Prevention) NPCR and National Cancer Institute SEER program. These 
data are collected and reported using standardized collection methods and are meant to 
include all cancers diagnosed in the U.S. Cancer primary site and histology were coded 
using the ICD-O-3.11
We examined all invasive, microscopically confirmed cases of cancer of the kidney and 
renal pelvis (ICD-O-3 primary site codes C64.9) diagnosed from 2001 to 2010 with known 
patient age which met USCS reporting criteria for each year from 2001 to 2010.12 A total of 
43 states and the District of Columbia, covering 91.3% of the U.S. population, met USCS 
reporting criteria for each year from 2001 to 2010. We excluded cases diagnosed by autopsy 
or death certificate only. RCC cases were defined as histology codes 8010 to 8051 and 8131 
to 8719. The clinical features of each cancer were described by SEER Summary stage 2000 
and SEER Derived Summary stage 2000 (localized, regional, distant and unstaged) and 
grade was defined as well differentiated (grade I) to undifferentiated, anaplastic (grade 
IV).13,14 Hispanic ethnicity included men and women of all race categories who were 
identified as Hispanic in the medical records or by use of a validated Hispanic/Latino 
Identification Algorithm.15 Racial groups examined included white, black, AIAN and API. 
Race and ethnicity were not mutually exclusive. Regional rates were calculated by 
aggregating the data for each state into the 4 U.S. Census regions.
For RCC we present total counts and incidence. Incidence rates were standardized to the 
2000 U.S. Standard Population (Census P25-1130) and are shown per 100,000 individuals. 
The CI limit was 95% and CIs were based on the gamma methods using the modification 
described by Tiwari et al.16 Age adjusted incidence rates are reported for gender, age, race, 
ethnicity, region, stage, grade and diagnosis year. Trends in incidence were calculated by the 
APC, that is the annual rate of change in incidence. Statistical significance in trend was 
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A total of 342,501 RCC cases were diagnosed from 2001 to 2010 with an age adjusted 
incidence rate of 12.1 cases per 100,000 population (see table). RCC incidence rates 
increased with age until ages 70 to 74 years with a peak incidence of 52.8. The RCC 
incidence rate in men was almost double that in women (16.4 vs 8.4). Most RCCs were 
diagnosed as localized disease (67.0%), followed by regional (14.5%) and distant (13.7%). 
Almost 38% of tumors were grade II and 20.3% were grade III while grade was unknown in 
25.1%. Only 11.6% of tumors were diagnosed as grade I and 5.1% were grade IV. From 
2001 to 2010 the age adjusted incidence rate of RCC increased significantly from 
10.6/100,000 individuals in 2001 to 12.4/100,000 in 2010. During this period the RCC 
incidence rate increased significantly in each gender (fig. 1). Overall black individuals had 
the highest incidence rate (12.6), followed by white (12.2) and AIAN individuals (11.9) 
while API individuals had the lowest incidence rate (5.4). Further analysis by gender and 
race showed that black men had the highest overall RCC incidence rate, almost double that 
of black women. This twofold difference in incidence rate by gender and race persisted in all 
races except AIAN (fig. 2). AIAN men had the third highest incidence rate (15.0) but AIAN 
women had the highest incidence by race among women (9.3).
RCC Incidence Trends
Given an observed increase in RCC (fig. 1), we focused on temporal trends in RCC, and 
demographic and clinical factors (see table). The APC was statistically significant in each 
gender but it was higher in women than in men (2.3 vs 1.9, see table). By age group the APC 
was higher in 4 younger groups (20 to 24, 25 to 29, 30 to 34 and 35 to 39 years) than in any 
of the other age groups. API showed the highest annual percent change at 2.7. When looking 
at differences by region, the West had the highest APC at 2.6. Localized stage showed the 
largest APC (4.3) and distant disease showed the lowest APC (0.7). APC was highest for 
grade III tumors (5.5), followed by grade II (5.1) and grade IV (3.7). When evaluating RCC 
for trends the increased incidence of RCC from 2001 to 2010 appeared to be primarily due 
to a steady increase in localized stage disease. However, these cases did not appear to be 
only low grade tumors since the largest increase was seen for grade II and III tumors (fig. 3).
DISCUSSION
To our knowledge this study is the first to use the USCS database to examine high quality 
incidence data on kidney cancer covering approximately 91% of the U.S. population. 
Previous studies, including the pioneering study in 1999 by Chow et al,2 examined the 
SEER database, which comprises less than 25% of the U.S. population.
Our study shows that the RCC incidence rate continued to increase from 2001 to 2010 with 
the largest APC increase in young adults, API individuals, and localized stage and grade III 
tumors. Although the highest incidence rates were seen in men, the greatest increase in 
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incidence was seen in women. Our study also revealed that while the highest RCC incidence 
rates were in those 70 to 74 years old, the fastest increase occurred in the younger age 
groups, especially those 20 to 24 years old. This increase in incidence was present for 
decades2 but only recently are we clearly seeing that younger age groups have the highest 
APC.
Our study provides a broader population based perspective supported by other recent 
findings. Using SEER data on 1975 to 2006 Nepple et al found a continuing increase in the 
RCC incidence.18 They noted no difference in the incidence rate between the genders. Our 
study showed a particular, marked increase in women, especially younger women, perhaps 
because it was based on almost the entire U.S. population. Another important contrast 
between our study and that by Chow et al, who looked at 1975 to 1995, was that we 
observed no difference in incidence rates between white and black individuals while their 
data demonstrated significant differences.2
The current results are of interest in a global context. The recently released GLOBOCAN 
2012 results show a worldwide increase in kidney cancer incidence rates with time 
compared to the GLOBOCAN 2008 and 2002 results.19 While the kidney cancer rate in 
some countries such as Sweden or Finland may be stabilized or possibly decreasing with 
time, the kidney cancer rate in countries such as the United Kingdom and China continues to 
increase. A potential explanation may lie in the increasing obesity rate in many countries, 
including the U.S. and United Kingdom, and in the increasing smoking rate in countries 
such as China.20
Some of the observed increase in RCC incidence such as the increase in localized stage may 
be related to an increase in advanced imaging, including computerized tomography, 
magnetic resonance imaging and positron emission tomography.21 However, we found an 
increasing incidence, especially in women and those 20 to 24 years old. More research is 
needed to determine whether either gender or any age group undergoes more imaging to 
explain in part the increased diagnosis of localized tumors. Likewise, if early detection is 
occurring through increased imaging, one would simultaneously expect to see an increase in 
the localized cancer rate and a decrease in the number of regionally advanced or unknown 
stage cases because tumors are being diagnosed at an earlier stage. This was not observed 
and similar increases were not seen for RPC, which would also be diagnosed more often as a 
result of increased imaging. The number of cases of regionally advanced disease did not 
change.
The increased RCC incidence appears to be primarily due to localized disease. However, 
these tumors should not be discounted. They may be clinically significant because the APC 
was highest for grade III tumors. Grade is a strong predictor of outcome.15 The 5-year 
survival rate for grade I and II tumors is 93% and 86% and there is markedly decreased 
survival in patients with grade III and IV tumors (66% and 42%, respectively).22 While a 
possible explanation is an upgrading phenomenon, which was observed for several cancers 
and most notably prostate cancer23 with the same prostate biopsy core upgraded with time, 
to our knowledge this has not been reported for kidney cancer. Thus, this increase in RCC 
diagnosis should not be ignored since these earlier stage tumors may also result in a large 
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impact on morbidity and mortality. We believe that other individual risk factors such as 
obesity and tobacco use should also be considered.
There is a generally accepted association between RCC and obesity.4,24 Obesity in younger 
age groups has been increasing for several decades and childhood obesity may have 
contributed to the higher APC in those 20 to 39 years old.25 Also, from 1999 to 2008 the 
prevalence of obesity (body mass index 30 kg/m2 or greater) in American women 20 to 39 
years old increased from approximately 28% to 34%.26 Adults of all races are still more 
likely to be obese than those in the younger age groups. However, in the last decade the 
prevalence of obesity has begun to stabilize in the general population while this younger age 
group continues to see an increase.25–27 We are uncertain whether a higher prevalence of 
obesity could result in a higher risk of RCC or whether obesity is instead a surrogate marker 
for other unmeasured confounders such as lack of physical activity, obesity driven 
inflammation, intake of processed or fat laden foods, or insulin resistance. While we could 
not investigate this potential link directly in this study, our results suggest that this warrants 
further investigation.
AIAN individuals had the third highest RCC incidence rates by race overall and AIAN 
women had the highest incidence rate by race. The literature addressing this is sparse but 
several potential factors are suspected to have a role.28 The cigarette smoking rate has 
decreased with time but a recent article showed that when grouped by race/ethnicity, 
nonHispanic AIAN individuals had the highest prevalence of cigarette smoking.29 
Additional research is needed to identify the possible effect of social determinants and other 
environmental risk factors.
The primary strength of this study is that USCS is a population based data set including all 
NPCR and SEER registries that met USCS publication criteria for all years, covering 91.3% 
of the U.S. population for 2001 to 2010.30 No other published study of kidney cancer 
epidemiology looked at this breadth of the U.S. population, including all races and 
ethnicities. Our cases were based on microscopic confirmation and standardized data 
collection protocols. Biases may impact the collection of information on cancer stage, 
especially unstaged cancer since patients with unstaged disease may have economic barriers 
to surgery and treatment that led to cancer being unstaged. Likewise, 25% of our cases were 
missing information on grade and, therefore, they may represent selection bias. Also, while 
we believe that smoking status and obesity may have a role, this information is not collected 
in cancer registries. A small number of cases may have been unaccounted for in the most 
recent year due to reporting delay but this is not believed to have affected the results.
CONCLUSIONS
We assessed the overall burden and trends of kidney cancer in the U.S. population from 
2001 to 2010. The incidence of RCC continued to increase with the largest increases in 
women, API individuals and those 20 to 24 years old. Likewise, while some of the increased 
incidence may have resulted from diagnosis of localized disease, the highest APC was seen 
in grade III tumors, a finding that may indicate more aggressive disease. Continued 
monitoring of RCC trends is warranted. Further epidemiological study of potential 
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contributing risk factors is needed to gain a better understanding of these types of kidney 
cancer and identify opportunities to reverse increasing trends.
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AIAN American Indian/Alaska Native
APC annual percent change
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RCC renal cell carcinoma
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RCC incidence and APC by gender and year in U.S. from 2001 to 2010. Data cover about 
91.3% of U.S. population. Incidence rates are shown per 100,000 population, age adjusted to 
2000 U.S. Standard Population (19 age groups, Census P25-1130) standard. Percent changes 
were calculated using 1 year per end point and APCs were calculated using weighted least 
squares method. Asterisk indicates APC significantly different from zero (p <0.05).
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RCC incidence by gender and race in U.S. from 2001 to 2010. Data cover about 91.3% of 
U.S. population. Incidence rates are shown per 100,000 population, age adjusted to 2000 
U.S. Standard Population (19 age groups, Census P25-1130) standard.
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RCC incidence in U.S. from 2001 to 2010. A, by stage at diagnosis. B, by grade at diagnosis. 
Data cover about 91.3% of U.S. population. Incidence rates are shown per 100,000 
population, age adjusted to 2000 U.S. Standard Population (19 age groups, Census 
P25-1130) standard. Percent changes were calculated using 1 year per end point. APCs were 
calculated using weighted least squares method. Asterisk indicates APC significantly 
different from zero (p <0.05).
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